201 related articles for article (PubMed ID: 33772528)
1. Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
Belbezier A; Boccon-Gibod I; Bouillet L
Eur J Dermatol; 2021 Feb; 31(1):86-87. PubMed ID: 33772528
[No Abstract] [Full Text] [Related]
2. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria.
Dortas Junior S; Azizi G; Valle S
Ann Allergy Asthma Immunol; 2020 Oct; 125(4):486-487. PubMed ID: 32544531
[No Abstract] [Full Text] [Related]
3. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
Farrah G; Stevenson B; Lie K; Brusch A
Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
Skander D; Allenova A; Maurer M; Kolkhir P
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
[No Abstract] [Full Text] [Related]
5. Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab.
Cho YT; Fu KT; Yang CW; Chu CY
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):394-395. PubMed ID: 34102302
[No Abstract] [Full Text] [Related]
6. Omalizumab in chronic inducible urticaria: A real-life study of efficacy, safety, predictors of treatment outcome and time to response.
Yu M; Terhorst-Molawi D; Altrichter S; Hawro T; Chen YD; Liu B; Song XT; Zhao ZT; Maurer M
Clin Exp Allergy; 2021 May; 51(5):730-734. PubMed ID: 33522024
[No Abstract] [Full Text] [Related]
7. The response to treatment in chronic spontaneous urticaria depends on how it is measured.
Weller K; Church MK; Metz M; Hawro T; Ohanyan T; Staubach P; Maurer M
J Allergy Clin Immunol Pract; 2019; 7(6):2055-2056.e4. PubMed ID: 30731179
[No Abstract] [Full Text] [Related]
8. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab.
Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC
J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438
[No Abstract] [Full Text] [Related]
9. Addition of omalizumab to antihistamine treatment in chronic urticaria: A real-world study in China.
Chen YD; Maurer M; Yu M; Tu P; Zhao ZT
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):217-219. PubMed ID: 32371240
[No Abstract] [Full Text] [Related]
10. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
Di Leo E; Calogiuri G; Macchia L; Nettis E
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
[No Abstract] [Full Text] [Related]
11. Baseline D-dimer plasma levels correlate with disease activity but not with the response to omalizumab in chronic spontaneous urticaria.
Asero R; Marzano AV; Ferrucci S; Genovese G; Cugno M
Allergy; 2019 Dec; 74(12):2538. PubMed ID: 31165493
[No Abstract] [Full Text] [Related]
12. COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases.
Ayhan E; Öztürk M; An İ; Bekçİbaşi M
Int J Dermatol; 2021 Feb; 60(2):253-254. PubMed ID: 33332576
[No Abstract] [Full Text] [Related]
13. Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
Hayama K; Fujita H; Asai-Sato M; Kawana K; Terui T
Eur J Dermatol; 2021 Feb; 31(1):100-101. PubMed ID: 33459258
[No Abstract] [Full Text] [Related]
14. Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence.
Tonacci A; Nettis E; Asero R; Rossi O; Tontini C; Gangemi S
Eur Ann Allergy Clin Immunol; 2020 May; 52(3):100-103. PubMed ID: 32108461
[TBL] [Abstract][Full Text] [Related]
15. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
Salman A; Ergun T; Gimenez-Arnau AM
J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
[No Abstract] [Full Text] [Related]
16. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
[TBL] [Abstract][Full Text] [Related]
17. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
[No Abstract] [Full Text] [Related]
18. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab for chronic urticaria in children younger than 12 years.
Al-Shaikhly T; Rosenthal JA; Ayars AG; Petroni DH
Ann Allergy Asthma Immunol; 2019 Aug; 123(2):208-210.e2. PubMed ID: 31082483
[No Abstract] [Full Text] [Related]
20. Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria.
Spekhorst LS; van den Reek JMPA; Knulst AC; Röckmann H
Allergy; 2019 Jun; 74(6):1185-1187. PubMed ID: 30593687
[No Abstract] [Full Text] [Related]
[Next] [New Search]
